Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 31Carcinoma, Intraductal, Noninfiltrating 3Ovarian Neoplasms 2Neoplasms 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Locoregional Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Granulosa cell tumor of the ovary 1Endometrial Neoplasms 1Carcinoma, Ductal 1Breast Carcinoma In Situ 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Carcinoma 1Advanced Breast Cancer 1Acrocephalosyndactylia 1

Interventions

Tamoxifen 7Specimen Handling 7exemestane 3Letrozole 3Anastrozole 3Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Biopsy 2ruxolitinib 1poly ICLC 1fezolinetant 1elacestrant 1Testosterone 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Selective Estrogen Receptor Modulators 1Radiotherapy 1Radiation 1Protons 1Proton Therapy 1Omacor 1Neoadjuvant Therapy 1Multicenter Studies as Topic 1Metformin 1Medicare 1Mastectomy, Segmental 1Mastectomy 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × exemestane × 90 days × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡